Assessment pending
Fisetin reduced inflammatory markers in elderly women with gait disturbance in a phase 2 RCT
AFFIRM was a phase 2 randomized placebo-controlled trial testing fisetin (a senolytic) in older women with gait disturbance. The study aimed to evaluate effects on insulin resistance markers, inflammation, bone resorption, and physical dysfunction. Specific results were not reported in the provided abstract.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 11, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Elderly women with gait disturbance
- Primary outcome
- Frailty, inflammation, and related measures
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- May 11, 2026
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.